News
Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...
Dr Dinesh Pendharkar highlights how CAR T–cell therapy is reshaping cancer care in India by equipping the immune system with ...
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...
1d
Medpage Today on MSNEmerging Myasthenia Gravis TreatmentsIn recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...
2d
Stockhead on MSNASX biotechs join global race for cell therapy breakthroughsSeveral ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...
While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.
I’ve endured numerous rounds of radiation and taken thousands of pills—but CAR-T is the most effective therapy I’ve completed ...
5d
News-Medical.Net on MSNStudy unveils powerful strategy to rejuvenate effectiveness of CAR T cell therapy against glioblastomaA team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...
Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial, highlighting the long-term efficacy and durability of ciltacabtagene autoleucel in multiple myeloma.
Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results